Zoetis Inc. (NYSE:ZTS) Stock Holdings Lifted by Orser Capital Management LLC

Orser Capital Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 1.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 8,960 shares of the company’s stock after buying an additional 103 shares during the quarter. Zoetis makes up 1.5% of Orser Capital Management LLC’s portfolio, making the stock its 25th biggest position. Orser Capital Management LLC’s holdings in Zoetis were worth $1,516,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZTS. Blue Bell Private Wealth Management LLC lifted its position in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its position in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Private Wealth Management Group LLC acquired a new position in Zoetis during the 4th quarter valued at about $33,000. Ramirez Asset Management Inc. acquired a new position in Zoetis during the 3rd quarter valued at about $35,000. Finally, Gladius Capital Management LP acquired a new position in Zoetis during the 4th quarter valued at about $40,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 1.7 %

Shares of Zoetis stock traded up $2.91 during trading on Friday, hitting $171.09. The stock had a trading volume of 4,899,668 shares, compared to its average volume of 2,118,600. The stock has a 50 day simple moving average of $166.56 and a 200 day simple moving average of $179.20. The company has a market capitalization of $78.07 billion, a PE ratio of 32.97, a P/E/G ratio of 2.61 and a beta of 0.88. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company posted $1.31 earnings per share. On average, research analysts expect that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.01%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 33.33%.

Analyst Upgrades and Downgrades

Several research firms have commented on ZTS. The Goldman Sachs Group lowered their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Stifel Nicolaus lowered their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. HSBC lowered their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, Barclays lowered their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average target price of $211.75.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.